Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01105247 · ClinicalTrials.gov registry record · Phase 1
Safety of PCI-32765 in Chronic Lymphocytic Leukemia
A Phase 1 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 1
- Development phase
- 133
- Enrollment target
NCT01105247 is a Phase 1 study that has completed, run by Pharmacyclics. The registered enrollment target is 133 participants.
The verdict
NCT01105247, a Phase 1 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 133 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the safety and efficacy of orally administered PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Interventions
- DRUG PCI-32765
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01105247
The ClinicalTrials.gov registry entry for NCT01105247 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PCI-32765 is the first listed.
NCT01105247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01105247 about?
NCT01105247 is a clinical study titled "Safety of PCI-32765 in Chronic Lymphocytic Leukemia". The purpose of this study is to establish the safety and efficacy of orally administered PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
What is the current status of trial NCT01105247?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 133 participants. The study started on 2010-05. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01105247?
The interventions under investigation include: PCI-32765 (DRUG).
Who is sponsoring clinical trial NCT01105247?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.